AstraZeneca falls on reports of merger talks with Bristol Myers Squibb
AZN•Reporting details
Reuters could not determine whether the talks are ongoing. The Financial Times first reported the news.
AZN is down 14.6% year to date.
AstraZeneca shares fall on merger talk reports
AstraZeneca's AZN.L shares were down 6.7% at £117.9, making the stock the top loser on the FTSE 100 index .FTSE, which was down 0.05%.
AZN and Bristol Myers Squibb held preliminary talks about a possible combination that would create a pharmaceutical company with a combined value of nearly $400 billion, a person familiar with the situation told Reuters.
